Organon announced the launch and product availability of Aybintio®, a biosimilar of Avastin®, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal and malignant glioma (WHO Grade IV) - glioblastoma.
"Organon Canada is committed to expanding its biosimilar portfolio to help strengthen our healthcare system and support patients in need," said Michael Casia, President and Managing Director, Organon Canada. "The impact of COVID-19 continues to put pressure and strain on our healthcare system across Canada. The adoption of biosimilars that are available at a reduced cost, such as Aybintio®, can help alleviate these burdens."
With the company's experience in biosimilars, the launch of Aybintio® represents Organon Canada's first entry in Oncology.
Continued advancement and availability of biosimilars provides patients impacted by aggressive cancers more affordable and alternative treatment options. Some of these cancers include non-small cell lung cancers; lung cancer, which is the leading cause of cancer death in both women and men, and colorectal cancer, which is expected to be the fourth most diagnosed cancer, excluding non-melanoma skin cancer, in Canada in 2022. Colorectal cancer is the second leading cause of death from cancer in men and the third leading cause of cancer death in women. In addition, approximately 3,000 Canadian women will be diagnosed with ovarian cancer in 2022, and over half (1,950) will die from it.
"More affordable and alternative treatments are undeniably needed to support patients across Canada," said Dr. Sandeep Sehdev, Medical Oncologist, Ottawa Hospital Cancer Centre. "These highly regulated biologic medicines have the potential to improve patient care by increasing patient access to therapies."
Aybintio® was developed and manufactured by Organon's collaborator Samsung Bioepis which also developed and manufactured its other biosimilars portfolio including Hadlima®, Brenzys® and Renflexis®.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!